Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Vehicle-Controlled, Multi-Centre, Parallel-Group Study to Investigate the Safety, Tolerability, and Efficacy of GR1014 Cutaneous Gel as a Topical Radioprotector in the Prevention of the Radiodermatitis Occurring With Adjuvant Radiotherapy for Localised Breast Cancer After Lumpectomy

NCT07192588 is registered in ClinicalTrials.gov with Graegis Pharmaceuticals Ltd as lead sponsor.

NCT NCT07192588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Vehicle-Controlled, Multi-Centre, Parallel-Group Study to Investigate the Safety, Tolerability, and Efficacy of GR1014 Cutaneous Gel as a Topical Radioprotector in the Prevention of the Radiodermatitis Occurring With Adjuvant Radiotherapy for Localised Breast Cancer After Lumpectomy
Lead sponsor
Graegis Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 26, 2024
Completion date
October 30, 2026
Enrollment
273 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

radiodermatitis; acute